Long-term cognitive decline prediction based on multi-modal data using Multimodal3DSiameseNet: transfer learning from Alzheimer's disease to Parkinson's disease

基于多模态数据的长期认知衰退预测:利用Multimodal3DSiameseNet从阿尔茨海默病到帕金森病的迁移学习

阅读:1

Abstract

PURPOSE: Monitoring and predicting the cognitive state of subjects with neurodegenerative disorders is crucial to provide appropriate treatment as soon as possible. In this work, we present a machine learning approach using multimodal data (brain MRI and clinical) from two early medical visits, to predict the longer-term cognitive decline of patients. Using transfer learning, our model can be successfully transferred from one neurodegenerative disease (Alzheimer's) to another (Parkinson's). METHODS: Our model is a Deep Neural Network with siamese sub-modules dedicated to extracting features from each modality. We pre-train it with data from ADNI (Alzheimer's disease), then transfer it on the smaller PPMI dataset (Parkinson's disease). We show that, even when we do not fine-tune the filters learnt from the ADNI MRIs, the transferred model's results are satisfying on PPMI. RESULTS: The first main result is that our model provides satisfying long-term predictions of cognitive decline from any pair of early visits, with no fixed time delay between these visits (provided the potential decline has started at the second visit). The second main result is that the prediction performance on Parkinson's dataset (PPMI) reaches an AUC of 0.81 on PPMI after transfer learning from Alzheimer's dataset (ADNI), without even having to re-train the image filters, versus an AUC of 0.72 for the model trained from scratch on PPMI. CONCLUSIONS: First, our model is effective for predicting long-term cognitive decline from only two visits, even with irregular intervals of time. When dealing with neurodegenerative diseases, where patients often miss some control visits, this is an important finding. Second, our model is able to transfer the knowledge learnt from one neurodegenerative disease (Alzheimer's) to another (Parkinson's), when using the same imaging modalities (brain MRI) and different clinical variables. This makes it usable even for diseases that are rare or under-studied.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。